-
公开(公告)号：US20190300609A1
公开(公告)日：2019-10-03
申请号：US16218797
申请日：2018-12-13
发明人： Gerhard Zugmaier , Evelyn Degenhard
摘要： The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19×CD3 bispecific single chain antibody construct to an adult patient in the need thereof.
-
公开(公告)号：US20210284732A1
公开(公告)日：2021-09-16
申请号：US17264386
申请日：2019-07-30
发明人： Gerhard Zugmaier , Max Topp , Gerd Munzert
IPC分类号： C07K16/28
摘要： The present disclosure relates to an antibody construct comprising a first domain which binds to BCMA and a second domain which binds to CD3, for use in the treatment or amelioration of a BCMA positive neoplasm, wherein the antibody construct is administered at a specified dose in at least one cycle, wherein one cycle comprises a specified period of administration of the antibody construct. Moreover, the disclosure relates to a method for the treatment of a BCMA positive neoplasm comprising administering a specified amount of such antibody construct, and the use of such antibody construct for the manufacture of a medicament for the treatment of a BCMA positive neoplasm.
-
公开(公告)号：US10696744B2
公开(公告)日：2020-06-30
申请号：US14885404
申请日：2015-10-16
发明人： Gerhard Zugmaier , Dirk Nagorsen , Juergen Scheele
IPC分类号： C07K16/28 , A61K39/395 , A61K39/00
摘要： The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19×CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of, in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, “BiTE”) is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.
-
4.发明申请公开(公告)号：US20190127465A1
公开(公告)日：2019-05-02
申请号：US16094172
申请日：2017-04-18
摘要： The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.
-
5.发明申请PPS for the prevention of potential adverse effects caused by CD3 specific binding domains 有权PPS用于预防CD3特异性结合结构域引起的潜在不良反应公开(公告)号：US20140228316A1
公开(公告)日：2014-08-14
申请号：US14176089
申请日：2014-02-08
发明人： Peter Kufer , Dirk Nagorsen , Juergen Scheele , Gerhard Zugmaier , Matthias Klinger , Patrick Hoffmann , Virginie Naegele , Elaine-Pashupati Dopfer
IPC分类号： A61K31/737
CPC分类号： A61K31/737
摘要： The present invention relates to a PPS for use in the amelioration, treatment or prophylaxis of neurological adverse events caused by a CD3 binding domain. Kits comprising a PPS, a CD3 binding domain and instructions for use which indicate that the PPS is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
摘要翻译： 本发明涉及用于改善，治疗或预防由CD3结合结构域引起的神经不良事件的PPS。 还公开了包含PPS，CD3结合结构域的试剂盒和用于指示PPS用于治疗由所述CD3结合结构域引起的神经功能不良事件的改善和/或预防的使用说明书。
-
公开(公告)号：US20240197989A1
公开(公告)日：2024-06-20
申请号：US18287046
申请日：2022-04-27
CPC分类号： A61M5/1723 , A61M5/14248 , G16H20/17 , G16H40/67 , G16H50/30 , G16H80/00 , A61M2205/18 , A61M2205/3303 , A61M2205/3553
摘要： A system for out-patient treatment with immunotherapy that activates T cells of a patient to fight cancer is provided that may include an infusion pump; a patient wearable device configured to acquire sensor data related to detection of cytokines released by the patient in response to the patient receiving the immunotherapy that activates T cells; and remote wireless communication with a healthcare provider based on the acquired sensor data. A computer-readable medium having computer-readable instructions stored thereon that, when executed by a processor, cause the processor to monitor health of a patient may include a sensor data receiving module that, when executed by a processor, causes the processor to receive sensor data; and a warning data generation module that, when executed by a processor, causes the processor to generate at least one warning based on the sensor data, wherein a content of the sensor data is based on an out-patient treatment that includes an immunotherapy that activates T cells of the patient.
-
公开(公告)号：US20240109964A1
公开(公告)日：2024-04-04
申请号：US18164304
申请日：2023-02-03
发明人： Gerhard Zugmaier , Evelyn Degenhard
CPC分类号： C07K16/2809 , C07K16/2803 , C07K16/468
摘要： The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to an adult patient in the need thereof.
-
公开(公告)号：US20220204620A1
公开(公告)日：2022-06-30
申请号：US17605061
申请日：2020-04-29
发明人： Gerhard Zugmaier , Max Topp
摘要： The present invention relates to a method of treating Burkitt lymphoma or leukemia in a patient, the method comprising administering to said patient a composition comprising a CD19×CD3 bispecific antibody in at least one treatment cycle, wherein the treatment cycle comprises administering a first dose of 15 μg/m2/d of the CD19×CD3 bispecific antibody for a first period of time of 4 days, and administering after the first dose a second dose of 60 Kg/m2/d of the CD19×CD3 bispecific antibody for a second period of time, wherein the second period of time exceeds the first period of time.
-
公开(公告)号：US11053318B2
公开(公告)日：2021-07-06
申请号：US16094172
申请日：2017-04-18
IPC分类号： A61K39/395 , C07K16/28 , A61P35/02 , C07K16/30 , A61K39/00
摘要： The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.
-
公开(公告)号：US09688760B2
公开(公告)日：2017-06-27
申请号：US14176091
申请日：2014-02-08
发明人： Peter Kufer , Dirk Nagorsen , Juergen Scheele , Gerhard Zugmaier , Matthias Klinger , Patrick Hoffmann , Virginie Naegele , Elaine-Pashupati Dopfer
IPC分类号： C07H21/04 , C07C43/00 , C07C49/00 , C07C237/26 , C07C331/00 , C12P21/08 , A01N37/18 , A61K31/65 , A01N31/00 , A61K31/095 , G01N33/00 , C12N5/071 , C07K16/28 , A61K31/10 , A61K39/395 , C07K16/18 , G01N33/50 , A61K39/00
CPC分类号： C07K16/2809 , A61K31/10 , A61K31/65 , A61K39/3955 , C07K16/18 , C07K2317/70 , G01N33/5008 , G01N2500/04
摘要： The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20×CD3 or a CD19×CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment. Such anti-adhesive type compounds include, but are not limited to, antibodies, like natalizumab, efalizumab, and etrolizumab; minocycline, (acetyl-)salicyclic acid, astilbin, and flavonoids; and thrombin and pentosanpolysulfate (PPS), or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.024 秒)
